Introduction
Apoptosis is a highly regulated and altruistic form of cellular demise resulting ultimately in the recognition and engulfment of moribund cells by neighbouring phagocytes. 1 The delicate balance between mitosis and apoptosis is recognized as an important determinant in the maintenance of homeostasis within the organism. Consequently, the dysregulation of apoptosis has been implicated in a plethora of human diseases and this, in turn, suggests that the apopotic process may be amenable to specific therapeutic intervention. 2 Hanahan and Weinberg, 3 in their recent overview of the hallmarks of cancer, have included the evasion of apoptosis among the essential alterations in cell physiology that dictate whether a cell becomes cancerous. Hence, the ability of tumor cell populations to expand in number is determined not only by the rate of cell proliferation, but also by the rate of cell death. 3 The emerging view is one of apoptosis as a barrier to cancer that must be circumvented, or in the words of apoptosis pioneer Andrew Wyllie, apoptosis can be likened to 'a ticket within a ticket' which has to be cancelled before reaching cancer. 4 Examples of resistance to apoptosis in cancer include the chromosomal translocation and subsequent upregulation of the anti-apoptotic bcl-2 oncogene in follicular lymphoma, and the commonly occurring loss in human cancer of the p53 tumor suppressor gene product, a key sensor of genomic insult capable of inducing pro-apoptotic signaling cascades within the damaged cell. Substantial evidence has accumulated in recent years for a central role of a family of cysteine proteases, termed caspases, in the orchestration of apoptotic destruction evidenced both in normal and malignant cells. The present review aims to provide an account of conventional, ie apoptotic, and non-conventional roles of the caspases, with particular emphasis on the potential importance of caspases in the treatment of lymphoid malignancies.
The caspases: a unique class of proteases
The caspases (for cysteine aspartate-specific proteases) are a family of proteases with a unique and stringent requirement for cleavage after Asp residues, shared only by the apoptogenic serine protease granzyme B. The caspases can be divided into several subfamilies based on phylogenetic analyses and positional scanning studies of their respective peptide recognition sequences (for review, see Ref. 5) . Caspase homologues are also found in lower organisms such as Caenorhabditis elegans and Drosophila melanogaster, thus providing evidence for the existence of a core 'death' machinery which has been preserved through evolution. 6 The most well-studied apoptotic signaling pathway involves ligation of the death receptor, Fas (also known as APO-1 or CD95), resulting in the assembly of a so-called death-inducing signaling complex (DISC). The adaptor molecule FADD (Fas-associated death domain-containing protein) is a central component of the DISC and serves to recruit the most apical caspase, termed pro-caspase-8 or FLICE (for FADD-like ICE), in what is currently thought to be a cascade of proteolytic activity reminiscent of the cascade observed during the activation of coagulation factors in the blood. Activation of caspases upon adaptor-mediated clustering can be explained by the unusual property of caspase zymogens to autoprocess to an active form. 7 In addition to DISC assembly and caspase recruitment at the plasma membrane, a second platform for caspase activation exists downstream of mitochondria. This protein complex, termed the apoptosome, consists of multimeric APAF-1 (apoptotic protease-activating factor-1), in conjunction with pro-caspase-9 and cytochrome c. 8 Mitochondria also provide means for amplifying death receptor-signaling through the release of a number of intermembrane space-resident molecules, such as cytochrome c and apoptosis-inducing factor (AIF), a flavoprotein which translocates to the nucleus during apoptosis and causes caspase-independent chromatin condensation and large-scale DNA fragmentation. 9 There are currently 14 members of the mammalian caspase family, several of which display overlapping specificities and apparent redundancy (see for example Ref. 10) . By contrast, lower organisms such as C. elegans seem to manage with a far more limited repertoire of 'death' proteases. Therefore, it remains a distinct possibility that some mammalian caspases perform functions which are not related to cell death. Intriguingly, another central player in 1 Importantly, the occurrence of necrosis is thought to be determined, not by factors intrinsic to the cell itself, but rather by violent environmental perturbations such as severe hypoxia or ischemia, or disruption of the plasma membrane by complement attack. 1 However, this die-hard dichotomous view of death has recently been challenged as more attention is focused on caspase-independent modes of cellular demise. 12 The first report on 'programmed' cell death in the absence of caspase activation was provided by Xiang et al, 13 who found that Bax-triggered death of the leukemic Jurkat T cell line was caspase-independent and transpired with necroticlike morphological features. Also, in murine tumor cells treated with agonistic Fas antibodies cell death was apoptotic, whereas pretreatment of cells with a pan-caspase inhibitor appeared to switch the mode of cell death towards necrosis. 14 Another example of a 'switch' which determines the outcome, ie apoptotic or necrotic cell death, of a given stimulus is the level of intracellular ATP. 15, 16 In addition, Déas et al 17 showed that anti-CD2 treatment of normal peripheral T lymphocytes in the presence of caspase inhibitors caused cell death characterized by necrotic-like features. A recent example, of potential importance for the treatment of chronic lymphocytic leukemia (CLL), was provided by Mateo et al. 18 These investigators showed that ligation of the novel thrombospondin
Figure 1
Emerging roles of mammalian caspases. In this hypothetical scheme, caspases control cell numbers through numerous mechanisms, including proliferation, differentiation and apoptosis. In addition, caspases have been shown to play a role in cytokine processing during inflammation.
Leukemia receptor, CD47, induced cytoplasmic features of apoptosis in CLL cells which were unaffected by the addition of caspase inhibitors. The above data have been taken to suggest that several instances of programmed cell death may have a necrotic face under the mask of apoptosis, and it was proposed that necrotic cell death should be subdivided into passive ('classical') necrosis and programmed ('necrosis-like') death. 12 An alternative explanation is that necrosis merely serves as a default mechanism under conditions where the 'apoptotic' caspases are incapacitated, resulting in cell death which lacks the morphological attributes of apoptosis. Indeed, it has been argued that apoptosis should be redefined in biochemical terms as caspase-dependent cell death with associated classical morphological features, ie nuclear condensation and fragmentation, cell shrinkage, formation of 'apoptotic bodies' and labeling of cells for phagocytosis. 19 In addition to non-apoptotic cell death, which is evidently caspase-independent, a growing number of studies have documented a role for proteases other than the caspases in cell death with apoptotic morphology. 20 For instance, the calcium-activated protease, calpain, has frequently been implicated in the apoptotic process, although it is presently unclear whether calpain and caspase activities are ordered in a hierarcheal or autonomous fashion. Interestingly, calpain was recently reported to serve as a potential regulator of caspases through cleavage and activation (or inactivation) of caspase-3, -7 and -9, 21-24 whereas other investigators have suggested that the reverse may also occur, ie calpain activation may be secondary to the activation of caspases, at least during drug-induced killing of leukemic cells. 25 A further level of complexity in the interplay between these classes of proteases is provided by the observation that caspases can cleave and dismantle the endogenous calpain inhibitor, calpastatin. 26, 27 Another non-caspase protease involved in apoptosis was described recently. 28 The authors showed that this 24 kDa serine protease (AP24) is involved in the fragmentation of DNA and that caspase-3 activation is insufficient to commit leukemic cells to apoptosis under conditions where the activation of AP24 is inhibited. 28 Moreover, the lysosomal protease, cathepsin D, was found to be involved in the Fas-and TNFtriggered pathways. 29 Both, cathepsin D antisense RNA and pepstatin A (an inhibitor of cathepsin D), protected cells from apoptosis mediated by these related death receptors. Of interest, other cathepsins have also been incriminated in apoptotic signaling. Thus, caspase-7 was reported to be activated by cathepsin G through cleavage of the zymogen at a noncanonical cleavage site, 30 and cathepsin B was described by Vancompernolle et al 31 to process a number of caspases, albeit with different selectivity. Moreover, cathepsin B was found to be involved in the proteolytic detachment of chromatin from the nuclear matrix and to contribute to the activation of the endonuclease that is responsible for generating high molecular weight chromatin fragments. 32 Finally, the nuclear scaffold (NS) protease, which is involved in the caspase-independent proteolysis of lamin B during apoptosis, 33, 34 was recently shown to be required for glucocorticoid-and nucleoside analog-induced apoptosis of CLL lymphocytes. 35 Intriguingly, addition of NS protease inhibitors alone sufficed to induce apoptosis in glucocorticoid-resistant CLL lymphocytes, most likely through an inhibition of NFB. 36 Future studies will reveal to what extent these classes of proteases with various subcellular localization and substrate specificities determine the ultimate fate of the cell.
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Caspases in inflammation, proliferation and differentiation
Caspase-1 was originally identified as an interleukin (IL)-1␤ converting enzyme and was therefore designated ICE. 37 Caspase-1 null mice develop normally suggesting that caspase-1 is not required for apoptosis during development. 38, 39 Indeed, conclusive evidence has been provided that caspase-3, but not caspase-1, is involved in Fas-mediated apoptosis. 40 Similarly, the deletion of caspase-11 (the murine homologue of caspase-4) in mice did not result in a significantly altered death phenotype. 41 On the other hand, these mice were resistant to septic shock due to the deficient activation of caspase-1 and subsequent cleavage of pro-IL-1␤. Thus, caspase-1 and -11 in mice (and probably their closely related human homologs, caspase-1, -4 and -5) are not involved in the direct transmission of apoptotic signals, and are more likely to be important for cytokine processing and inflammation. Interestingly, caspase-3, the prototypic 'death' protease, was recently shown to play a role in the maturation of IL-16, 42 thereby attesting to the pleiotropic functions of these proteases.
FADD is a cytosolic Fas-binding adaptor molecule which is required for Fas-and TNF type I receptor-mediated killing and serves to recruit pro-caspase-8 to the DISC (discussed above). Inhibition of FADD function by gene targeting or by expression of a dominant negative mutant of FADD renders cells resistant to Fas ligand-induced apoptosis, and unexpectedly, inhibits mitogen-induced T cell proliferation. 43, 44 Hence, these data suggest that FADD may serve as a conduit into the cell not only for apoptotic signals, but also for growth and/or survival signals. Moreover, recent studies have indicated that FADD mediates a signal for proliferation during the transition from the pro-T to the pre-T stage during thymocyte development and suggested that FADD can also function as a tumor suppressor. 45 Moreover, ligation of Fas in vitro was also shown to signal proliferation in human diploid fibroblasts, T lymphocytes and certain B-CLL cells. [46] [47] [48] On the other hand, Fas stimulation was recently shown to prevent store-operated calcium entry in T lymphocytes, an event which is required for T cell functions such as proliferation, cytokine generation and differentiation. 49 Evidently, Fas, in analogy with the related TNF type I receptor, serves several opposing functions and is not restricted to apoptosis signaling.
Activation of caspase-3-like enzymes in non-apoptotic T lymphocytes was first reported by Miossec et al, 50 and these data were further supported by Wilhelm et al, 51 who provided evidence for caspase-mediated cleavage of PARP in the absence of DNA fragmentation and apoptosis. Other investigators have argued that artefactual, granzyme B-mediated activation of caspases might account for these findings. 52 However, recent data appear to confirm that caspases are, indeed, activated in non-apoptotic T lymphocytes and furthermore, that caspases may be required for T cell proliferation in vitro, as the addition of cell-permeable caspase inhibitors impedes proliferation of these cells. 53, 54 Moreover, Alam et al 53 observed activation of caspase-3, -6, -7 and -8 and cleavage of well-known caspase substrates, such as PARP, upon T cell activation, while other substrates such as DFF45 were spared, thus likely avoiding 'apoptotic' fragmentation of DNA in these cells. On the other hand, Kennedy et al 54 observed activation of caspase-8, but failed to detect activation of caspase-3 or degradation of PARP in activated T lymphocytes.
By which mechanism(s) are activated T lymphocytes protected from accidental apoptosis? Is there a critical threshold of caspase activity which determines whether a cell should live or die? Are the caspases sequestered away from their critical 'death substrates' in healthy cells, or are they held at bay by endogenous caspase inhibitors which prevent the fullblown cascade of proteolytic events leading to selfannihilation? Kennedy et al 54 have suggested that FLIP (FLICEinhibitory protein) might serve as a 'substrate trap' for caspases in activated lymphocytes, thus thwarting the 'death programme' under conditions of T cell activation. Interestingly, FLIP expression in T lymphocytes was recently shown to be regulated in a cell cycle-dependent manner, possibly accounting for the differential susceptibility to Fas-mediated apoptosis following TCR stimulation. 55 Another potential candidate is the Fas-associated phosphatase, FAP-1, which negatively regulates Fas-mediated apoptosis 56 and is down-regulated in activated T lymphocytes. 57 Also worth noting are the recent observations by Jäättelä et al, 58 who found that elevated levels of heat shock protein 70 protected tumor cells from death despite the conspicuous presence of cytochrome c in the cytosol and caspase-dependent cleavage of nuclear 'death' substrates, although the mechanism of survival of cells which have sustained damage to vital repair enzymes, such as PARP, remains to be elucidated. Finally, the possible involvement of the alternative Fas-triggered DAXX/JNK/SAPK pathway (discussed below) for these proliferative responses remains to be elucidated. In any event, the investigation of the role of caspases and death receptor signaling in non-apoptotic T lymphocyte responses remains one of the hot topics in apoptosis research.
The caspases have recently been implicated in the negative regulation of erythropoiesis. 59 Caspase-mediated cleavage of the transcription factor GATA-1 occurred during erythropoiesis in response to low doses of agonistic Fas antibody. Importantly, Fas ligation under these conditions blocked erythroid cell expansion and differentiation without triggering apoptosis. Another example of the involvement of caspases in non-apoptotic cell physiology is afforded by the observation that nuclear disintegration during terminal differentiation of lens fibers, a process which is promoted by the anti-apoptotic fibroblast growth factor, is caspase-dependent. 60 Finally, Watanabe and Akaike 61 found that caspases are involved in the maintenance of cytoskeletal integrity in adherent cells, an observation which challenges the current view that caspase activation inevitably leads to disintegration of the cytoskeletal structure. Hence, the functional repertoire of the caspases has been extended to encompass not only proliferation and inflammation, but also pro-and anti-differentiative effects ( Figure 1 ). The pivotal role of the caspases in apoptosis will be discussed in the following section.
The caspases as 'killer' proteases
Numerous studies have provided evidence for a role of the caspases as the effector machinery of apoptosis, the strongest argument being the close resemblance between the caspases and the C. elegans 'death' gene, ced-3. 62 Hence, it has now been established that: (1) caspase zymogens are processed during apoptosis; (2) the caspases target proteins whose cleavage is associated with apoptotic death; (3) broad-spectrum caspase inhibitors such as zVAD-fmk and p35 prevent apoptosis; (4) overexpression of various caspases results in apoptosis; and (5) deletion of specific caspases in mice leads to profound defects in apoptosis in vivo. 5, 63 In particular, the role of caspases in neuronal apoptosis was underscored by the striking phenotype of caspase-3 and caspase-9 knockout animals. In caspase-3 null mice, supernumerary cells were 1517 noted in the CNS by embryonic day 12, and the CNS abnormalities often resulted in embryonic lethality. 64 In addition, Woo et al 65 provided in vivo evidence for a critical role of caspase-3 in nuclear apoptotic changes in a tissue-and stimulus-specific manner. In caspase-9 knockout animals, caspase-3 was not activated, suggesting that caspase-9 acts upstream of caspase-3, and similar phenotypic features, ie embryonic lethality and defective brain development, were evident. 66, 67 Disruption of the caspase-8 gene was found to be lethal in utero, and the embryos were presumed to die, not from abnormal brain growth, but from cardiac failure.
68 Surprisingly, the heart of these animals was hypotrophic rather than enlarged, suggesting that caspase-8 may, in fact, be involved in the transmission of survival signals in addition to apoptotic signals. Finally, deletion of the caspase adaptor molecule APAF-1 yielded animals which closely resembled caspase-3-and caspase-9-deficient mice, with severe craniofacial abnormalities, brain overgrowth and reduced apoptosis in the CNS, while morphogenesis in other parts of the body was remarkably normal. 69, 70 Thus, the caspases may be viewed as 'killer' proteases which play an essential role in mammalian apoptosis. 63 The caspases are involved in structural disassembly of the cell, disabling of homeostatic and repair mechanisms, inactivation of apoptosis-inhibitory molecules, and tagging of the dying cell for engulfment and disposal. 5 In view of the everincreasing list of caspase substrates, which thus far includes more than 70 proteins, one could ask which cleavage events are critical for the emergence of apoptotic features. Indeed, while the rationale for caspase-mediated cleavage of cellular constituents can be predicted in several cases, the current view of apoptosis as death 'by a thousand cuts' 71 should perhaps be reassessed. Of note, human neutrophils, which undergo constitutive apoptosis with concomitant activation of caspases, lack a number of 'classical' caspase substrates including PARP, indicating that cleavage of these proteins is dispensable for the apoptotic process. 72 Interestingly, while the introduction of the non-specific protease, proteinase K, into intact cells results in digestion of caspase substrates together with the appearance of morphological signs of apoptosis, the pan-caspase inhibitor, zVAD-fmk prevented these morphological changes in the face of extensive protein destruction. 73 Hence, unbridled destruction of proteins per se does not suffice to commit a cell to apoptosis. Instead, the specific caspase-mediated activation of a subset of downstream effector molecules such as the actin-modulating protein gelsolin 74 and acinus, the 'apoptotic chromatin condensation inducer in the nucleus', 75 may be required. The notion that activation, not destruction, of proteins is critical for the stereotyped sequence of events that constitutes apoptosis may perhaps shed some light on the selective caspase-mediated substrate cleavage and absence of apoptosis which has been observed in activated T lymphocytes (discussed above). However, further work is needed to establish which caspases and which proteolytic caspase victims are critical for the implementation of apoptosis and whether cell type-specific differences exist (Figure 2 ).
Role of Fas/Fas ligand in drug-induced caspase activation
Most of the DNA-damaging agents currently employed in cancer treatment, including daunorubicin, doxorubicin, etoposide and mitomycin C, as well as fludorabine and flavopiridol, kill leukemic cells via activation of caspases. [76] [77] [78] The Fas sysLeukemia tem has recently been implicated in this event. [79] [80] [81] These authors proposed that certain anticancer drugs might initiate a paracrine or autocrine ('suicidal') death of tumor cells by upregulation of Fas and/or Fas ligand with subsequent ligation of Fas and initiation of the apoptosis cascade. 2-Chloro-2Ј-deoxyadenosine (2CdA)-induced apoptosis in human leukemic cells was also shown to proceed through the phosphorylation of 2CdA followed by the protein synthesis-dependent expression of Fas and Fas ligand and sequential activation of caspase-8 and -3. 82 In addition, an association between resistance to chemotherapy and resistance to Fastriggered apoptosis has been observed. 83, 84 However, the involvement of Fas in chemotherapy-induced apoptosis has not remained undisputed, as other investigators have provided evidence for Fas-independent pathways. [85] [86] [87] Indeed, detailed analysis of cross-resistance to Fas-mediated apoptosis and resistance to cytotoxic drugs showed that while both triggers use common apoptotic effectors, the point of convergence in these two pathways is likely to exist downstream of Fas/Fas ligand interactions. 88 In addition, Fulda et al 89 
Cells derived from caspase-3 and caspase-9 null animals are resistant to UV irradiation and cytotoxic drug-induced cell death, whereas Fas-and TNF receptor-mediated killing remains unperturbed. On the other hand, embryonic fibroblasts from FADD-and caspase-8-deficient animals retained their sensitivity to chemotherapeutic agents, suggesting that receptor-mediated signaling is not an essential requirement of drug-induced apoptosis (for review, see Ref. 90) . Moreover, mistletoe lectin, used as an adjuvant in cancer therapy, enhances the cytotoxic effect of chemotherapeutic drugs in leukemic B and T cell lines in vitro via stimulation of death receptor-independent, mitochondria-controlled activation of caspases. 77 Finally, a novel signaling event required for radiation-induced apoptosis in T lymphoma cells and independent of Fas/Fas ligand interaction has recently been suggested. 91 These authors provided evidence to suggest that ionizing radiation induces a rapid activation of caspase-8 and resultant cleavage of the pro-apoptotic substrate, Bid, and release of cytochrome c from mitochondria without involvement of the Fas system. Caspase-8 activation was not observed in cells genetically defective for the Src-like tyrosine kinase, Lck, and cells that lacked Lck also displayed a marked resistance to radiation-induced apoptosis. After retransfection of Lck, caspase-8 activation and the ability to undergo apoptosis in response to ionizing radiation was restored. Thus, caspase-8 might be activated via a Lck-controlled pathway independently of Fas ligand expression. In sum, Fas/Fas ligand signaling may not be essential for chemotherapy-or irradiationinduced caspase activation in leukemic cells.
Reciprocal interaction between kinases, transcription factors and caspases
Protein phosphorylation is the most common cellular mechanism for post-translational regulation of protein function and provides a suitable mechanism for the integration of conflicting extrinsic and intrinsic signals. In response to certain external cues, protein tyrosine kinases can alternate between different roles, and either stimulate apoptotic death or inhibit apoptosis and promote cell survival. 91 Indeed, the
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Figure 2
Regulation of caspases during apoptosis. Note that translocation of caspases within the cell may also occur prior to their activation. However, the mechanism(s) and signals involved in caspase translocation remain to be investigated. For further details consult text.
activation of PI-3-kinase, one of the targets of Src, leads to production of PtdIns(3,4,5) triphosphate, which serves as a specific membrane-linked ligand of the protein kinase B (PKB/Akt). Upon targeting to the membrane, activated Akt phosphorylates Bad, thereby preventing it from dimerizing with and blocking the anti-apoptotic activity of Bcl-2/Bcl-X L . 92 The same kinase phosphorylated FKHR1 (a transcriptional factor that regulates the expression of several apoptosis-inducing genes) and pro-caspase-9, the latter event resulting in the inhibition of processing and activation of the proenzyme. 93, 94 Although direct inhibition of pro-caspase-9 maturation via phosphorylation was recently questioned, 95 it is still possible that Akt might suppress caspase activation via targeting APAF-1, suppressors of caspase-9, such as XIAP, or other as yet unidentified proteins. 96 Another example of the involvement of kinases in apoptosis signaling is provided by DAXX (death domain-associated protein), originally characterized as a protein that binds the cytosolic domain of Fas and links this receptor to the activation of the c-jun N-terminal kinase (JNK)/stress-activated protein kinase (SAPK) pathway. 97 Surprisingly, recent studies have demonstrated that DAXX can localize to PML oncogenic domains (PODs) in the nucleus and exhibit the ability to repress transcription. 98 In acute promyelocytic leukemia cells, DAXX is detached from the nuclear domains and upon retinoic acid treatment, which induces disease remission, DAXX relocalizes to the PODs. 99 These authors suggested that upon treatment of cells with agents that attenuate POD formation, DAXX enhances cellular sensitivity to Fas-induced apoptosis, perhaps by modulating the transcription of genes involved in Fas-induced caspase activation and apoptosis. Finally, the p21-activated protein kinases (PAK-1 to -3) are closely related serine/threonine kinases activated by the GTPases Rac and Cdc42. 100 Although PAK-1 protects cells from apoptosis via phosphorylation of Bad, 101 PAK-2 is proteolytically cleaved by DEVDases (caspase-3 or -7) and is involved in the regulation of membrane and morphological changes occurring during apoptosis. 102 Taken together, these findings indicate a dual function of protein kinases in apoptosis, acting either upstream or downstream of caspases in a complex signaling network (Figure 2) .
Death induced through the Fas-related TNF type I receptor involves recruitment of pro-caspase-8, the apical protease in this pathway, and is tightly regulated by the transcription factor, NFB. Hence, modulation of the response in favour of NFB activation protects cells from TNF-mediated apoptosis, whereas failure to do so results in increased cell death. 103 The role of caspases in the regulation of these two conflicting pathways in lymphoma cells was recently described. 104, 105 Two proteins involved in the activation of NFB, the serine/threonine kinase RIP and TNF receptor-associated factor (TRAF-1), were found to be cleaved by caspase-8. This caspase-induced inactivation of anti-apoptotic proteins resulted in the generation of dominant negative fragments that inhibit further NFB activation, leading to amplification of the death signal and rapid apoptosis. Similar observations were made in a related study, in which growth factor withdrawal resulted in apoptosis of endothelial cells with attendant caspase-dependent cleavage and 'switch-off' of NFB. 106 Another caspase substrate involved in the regulation of cell survival, the proto-oncogene Vav1, was recently described. 107 Vav1 participates in the activation of the transcription factors NF-AT, AP-1 and NFB and also plays an important role in cytoskeletal reorganization. Upon apoptosis induction in lymphoma cells, caspase-8-mediated cleavage of this protein resulted in its inactivation. Since the caspase-dependent destruction of Vav1 affects several Vav1-dependent processes this event is presumably more economical than cleaving the numerous target proteins downstream of Vav1. Thus, caspases may play an important role in the promotion of apoptosis and concomitant prevention of cell survival signals.
Role of Bcl-2 upstream and downstream of caspases
Bcl-2 is a survival factor that negatively regulates cell death and its enhanced expression in B cell lymphomas was shown to result in increased survival of these cells. 108 Bcl-2 has been shown to prevent release of cytochrome c from mitochondria, thereby indirectly affecting APAF-1-mediated activation of caspase-9. 109, 110 However, the function of Bcl-2 and Bcl-X L is not solely due to the prevention of cytochrome c release from mitochondria, since overexpression of Bcl-2 protects cells from apoptosis downstream of Bax-induced cytochrome c release as well as after microinjection of cytochrome c. 111, 112 Moreover, it was suggested that Bcl-2 exerts its anti-apoptotic activity partly by inhibiting the translocation of Bax through the modification of cytosolic factors that are involved in translocation during apoptosis. 113 It has recently been shown that Bcl-2, as well as Bcl-X L , is cleaved by caspase-3 in cells undergoing apoptosis in response to Fas ligation or growth factor withdrawal, and the cleaved fragment was suggested to serve as a pro-apoptotic, Bax-like molecule in these cells. 114, 115 We recently observed cleavage of Bcl-2 in chemotherapy-treated cells of leukemic origin, and found that cleavage occurred predominantly in the mitochondrial fraction of these cells. 116 Since the regulation of cytochrome c release from mitochondria has been suggested to be a primary role for Bcl-2, it is feasible that caspase-mediated cleavage of Bcl-2 may lead to an increased leakage of cytochrome c from mitochondria with an ensuing activation of additional cytosolic caspases, thus serving as a feed-forward amplification loop for apoptosis signaling (Figure 2) . Indeed, this notion has since been confirmed by other investigators, who showed that transfection of the caspase-generated Bcl-2 fragment into baby hamster kidney cells caused cytochrome c to be discharged into the cytosol. 117 Therefore, chemotherapy-induced cleavage of Bcl-2 in lymphoid cells represents a possible mechanism for the inactivation of Bcl-2 and this event may serve to determine the susceptibility of tumor cells to apoptosis. Interestingly, inhibition of the ubiquitin-proteasome pathway activates caspase-3-like enzymes and induces Bcl-2 cleavage in human leukemic cells, 118 suggesting an additional level of cross-talk between different proteolytic activities within the cell.
The precise mechanism by which DNA damaging agents induce activation of caspases and subsequent apoptotic changes remains unknown, although Bcl-2 is known to suppress apoptotic signals from the nucleus. The so-called BH3-only pro-apoptotic proteins appear to function through binding to and neutralization of the anti-apoptotic Bcl-2 family proteins (for review see Ref. 119 ). RAD-9, a protein involved in cell cycle checkpoint control, was recently shown to interact with the anti-apoptotic proteins Bcl-2 or Bcl-X L through its BH3-like domain to promote apoptosis. 120 Importantly, RAD-9 does not interact with Bax or Bid, two other pro-apoptotic proteins, and hence does not rely on the established pro-apoptotic effects of these proteins for eliciting its own function. Following the treatment of tumor cells with DNA-damaging agents, RAD-9 protein displays only perinuclear immunostaining and a co-localization with Bcl-2. The perinuclear translocation of RAD-9, which is dependent on its BH3-like domain, precedes morphological changes characteristic of apoptosis. In conclusion, RAD-9 appears to regulate multiple downstream events including cell cycle checkpoint control and apoptosis, and as such to serve as a novel link between DNA damage and the death machinery of the cell.
Expression and activation of caspases in leukemic cells
Proteolytic cleavage of proteins is an irreversible event and mechanisms for the tight control of caspases are therefore of paramount importance. Although caspase zymogens are commonly thought to be expressed in latent form in most cells, there are several examples of caspase regulation at the transcriptional level in cancer cells (Figure 2) . Thus, heterogeneous expression of caspase-2, -3, -4 and -6 was observed in leukemic cell lines and bone marrow samples from patients with acute myelogenous leukemia. 121 Comparison of the profile of caspase-3 in lymphocytes from patients with Hodgkin's disease (HD) demonstrated that this enzyme is commonly expressed in classical HD, but only in one out of 11 cases of HD with nodular lymphocyte predominance. 122 Immunonegative staining of caspase-3 was observed in all small lymphocytic lymphomas, whereas peripheral blood B-CLL cells were caspase-3 positive. 123 Since small lymphocytic lymphomas are thought to represent a lymphomatous version of B-CCL, it is reasonable to assume that expression of caspase-3 may vary within malignant B cell lymphomas depending on the tissue compartments in which they reside in the body. The mantle zone B cells typically do not express immunodetectable amounts of caspase-3. By contrast, germinal center B cells express high levels of this protein. 123 Therefore, the expression of caspase-3 in B-CLL may represent an example of aberrant gene expression associated with the pathogenesis of B-CCL. 124 
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The so-called caspase recruitment domain (CARD) is critical for the recruitment and activation of pro-caspase-9 by APAF-1 downstream of mitochondria during apoptosis (for a review, see Ref. 125) . Recently, overexpression of bcl-10, a novel gene that encodes an amino-terminal CARD domain, was described. 126 Wild-type bcl-10 induced apoptosis and activated NFB in tumor cells, whereas this activity was lost in CARD truncation mutants. Moreover, it was shown that overexpression of inactivating mutations of bcl-10 might confer a survival advantage to mucosa-associated lymphoid tissue (MALT) lymphoma cells. 126 bcl-10 mutations were also detected in other types of tumors, indicating that this protein may be commonly involved in the pathogenesis of human cancer. 127 Of interest, NFB activation by bcl-10 was shown to involve CARD-dependent assembly of cytoplasmic filaments, suggesting that the cytoskeleton network may be involved in signaling during apoptosis. 128 Another protein with a CARD domain, ASC (for apoptosis-associated specklike protein containing a CARD), was recently identified in promyelocytic leukemia cells. 129 This novel protein was located in the cytosol and upon apoptosis induction it formed an insoluble aggregate and was visualized as a speck. Although the precise role of ASC in the apoptotic cascade is unknown, antisense oligonucleotides directed against ASC were shown to reduce etoposide-mediated apoptosis in leukemic cells.
Arsenic trioxide induces long lasting remission in patients with acute promyelocytic leukemia (APL) and the induction of pro-caspase-2 and -3 expression as well as the activation of caspase-1 and -3 was seen in cells obtained from these patients. 130 The ability of arsenic trioxide to induce apoptosis in leukemic cells depends on the activity of glutathione peroxidase and catalase, enzymes that regulate the cellular hydrogen peroxide level, and caspase-3 activation is preceded by an increase in hydrogen peroxide content. 131 Moreover, inhibition of glutathione peroxidase and catalase renders leukemic cells susceptible to low, clinically acceptable doses of arsenic trioxide. Of note, previous work has shown that oxidants, including hydrogen peroxide and dithiocarbamate disulfides, may play a dual role in the propagation of the apoptotic signal, exerting a long-term induction of apoptosis and a short-term inhibition presumably via a direct effect on the caspases. 132, 133 Upregulation of caspase genes was found in acute myelogenous leukemia (AML) cells upon treatment with etoposide and in CLL after fludarabine treatment, 121, 134 indicating an important role of these genes in tumor response to treatment. Indeed, a significant association between high levels of caspase-3 and achieving complete remission in acute lymphoblastic leukemia (ALL) has recently been demonstrated. 135 Promising gene therapy based on caspase-3 has also been undertaken. 136 Although transient expression of human caspase-3 was not sufficient to induce apoptosis in tumor cells, apoptosis in these cells was markedly enhanced by treatment with DNA-damaging drugs. The combined transduction of the caspase-3 gene and administration of etoposide resulted in extensive apoptosis as well as reduced tumor volume in an experimental liver tumor model. 136 Alternative splicing of caspase transcripts may also serve to regulate the outcome of apoptotic signaling, 137 and evidence for a dominant negative inhibition of caspase-9 activation by an endogenous caspase-9 variant missing the catalytic site was provided. 138 Recent data indicate that post-transcriptional/post-translational changes may also occur which can curtail caspase activation. Thus, phosphorylation of caspases, or other proteins reg-Leukemia ulating caspase activity, might result in altered tumor sensitivity to treatment 94, 96 (discussed above). In addition, subcellular compartmentalization of caspases is well established and may serve to keep the caspases safely sequestered away from their respective 'death' substrates. Hence, caspase-2, -3 and -9 are present in the mitochondrial intermembrane space in viable cells and are released into the cytosol during apoptosis, [139] [140] [141] [142] whereas caspase-12 was shown to reside in the endoplasmic reticulum. 143 Interestingly, defective apoptotic signaling downstream of caspase-3 in tumor cells was recently described. 144, 145 In both cases, absence of translocation of active caspase-3 from cytosol to nucleus resulted in the absence of nuclear apoptosis and continued growth of tumor cells.
A lack of expression of caspase-3, an 'effector' caspase involved in the cleavage of cellular substrates, in lymphoid tumors was associated with their resistance to apoptotic stimuli. 121 However, dysfunction in the activation of caspases may also influence the sensitivity of tumor cells to apoptosis. For instance, absence of pro-caspase-3 activation in some melanoma and leukemia cells, despite cytosolic translocation of cytochrome c and induction of mitochodrial permeability transition, resulted in resistance to apoptosis. 146 Loss of the Fanconi anemia group C protein results in an inability to activate caspase-3 after ionizing radiation and treatment with mitomycin C. 147 Processing and activation of caspase-3 and -7 was observed in spontaneous and drug-induced apoptosis in cells from patients with CLL. 148 In these experiments, limited activation of pro-caspase-8 (classified as an 'initiator' caspase) was also observed, while caspase-2 processing appeared not to be involved. Moreover, the absence of procaspase-8, as well as pro-caspase-1, -4 and -10, did not influence the sensitivity of tumor cells to drug treatment and irradiation. 149 In sum, it seems that the presence or absence of 'initiator' caspases, such as caspase-8 and -9, is important for the choice of drug treatment, and this, in turn, reflects whether a death receptor-mediated or mitochondria-based signaling pathway is utilized. However, the downstream activation and translocation of 'effector' caspases such as caspase-3 and -7 is likely to represent a point of convergence for various treatment regimens and will be important for the successful outcome of apoptotic triggering (Figure 2 ).
Viral and mammalian caspase inhibitors
Viruses have assimilated strategies for the inhibition of apoptosis in host cells (for review see Ref. 150 ). The first caspase inhibitor to be identified was the cowpox virus-encoded protein, crmA (cytokine response modifier A), which binds and inhibits caspase-1 and caspase-8. This protein structurally belongs to the serine protease inhibitor (serpin) group and like conventional serpins, crmA acts as a pseudosubstrate that binds to the active protease. Another viral protein, termed p35, is expressed in baculovirus and inhibits caspase-1, -3, -6, -7, -8 and -10. The mechanism of action of p35 is fundamentally different from crmA-mediated inhibition, since p35, upon introduction into mammalian cells, is cleaved by caspases and the cleaved subunits of p35 then remain in an inhibitory complex with the caspases. A common cause of the multidrug-resistant (MDR) phenotype of tumors is overexpression of the drug-effluxing P-glycoprotein. Cells induced to express P-glycoprotein either by drug selection or by retroviral gene transduction are resistant to cell death induced by a wide range of stimuli, such as Fas ligand, TNF-␣ and UV irradiation, all of which activate the caspase cascade. 151 However, the susceptibility of P-glycoprotein-expressing leukemia cells to caspase-independent cell death mediated by pore-forming proteins and granzyme B remained unaffected.
Recently, a new family of viral inhibitors named vFLIPs and their cellular homologues (cFLIPs; also known as iFLICE, FLAME-1, CASH, CLARP, MRIT or usurpin) were identified (for a review, see Ref. 152 ). These proteins possess a death effector domain (DED) and intervene at the level of the death receptor by inhibiting interaction between FADD and pro-caspase-8 (which also harbour DEDs). Recent in vivo experiments have provided compelling evidence that expression of FLIP confers a growth advantage for tumors within an immunocompetent setting. Hence, injection of cells expressing high amounts of FLIP into mice resulted in the establishment and aggressive growth of tumors. 153, 154 Although the role of FLIP in leukemia has not yet been assessed, the targeting of FLIPmediated inhibition of death receptor-triggered caspases in this type of cancer deserves further attention. Moreover, Zhang et al 155 have recently identified a novel multidomain protein termed BAR (bifunctional apoptosis regulator) that appears to bridge the death receptor-and mitochondriamediated apoptosis pathways. BAR contains a DED capable of suppressing apoptosis signaling through Fas, and another domain that mediates interactions with Bcl-2 and Bcl-X L and is required for suppression of Bax-induced death. BAR expression was noted in a variety of human tumor cell lines, and it will be of considerable interest to determine whether BAR can regulate susceptibilty to chemotherapeutic agents acting either through death receptor signaling or at the level of the mitochondrion.
The only known endogenous mammalian caspase inhibitors are the IAPs (inhibitor of apoptosis proteins). 156 Precisely how the anti-apoptotic IAPs function is not clear, although several mechanisms of sequential inhibition of caspase-9, -3 and -7 have been suggested. 157, 158 The expression of XIAP and HIAP, but not NAIP, in human malignant cell lines was suggested to play an important role in the resistance of these cells to apoptotic stimuli that directly target the caspases. 159 Moreover, the IAP family protein, survivin, while absent in normal differentiated tissues, is overexpressed in a large proportion of human cancers. 160 The expression of survivin correlates with the resistance of tumors to treatment and with shorter survival of these patients. Survivin expression was shown to be cell cycledependent and largely restricted to the G 2 /M phase, a period during which survivin binds to microtubules of the mitotic spindle, thereby enhancing interaction with target caspases. 161 Recently, evidence for the supramolecular assembly of caspase-3, survivin and the cyclin-dependent kinase inhibitor p21 waf1/cip1 within centrosomes was obtained, suggesting that control of apoptosis by survivin is required for mitotic progression. 162 BIR1, a yeast homologue of survivin, was also found to control cell division in Saccharomyces cerevisiae, albeit in the absence of an apoptotic programme. 163 These new insights into the mechanism of action of survivin are particularly intriguing in light of the finding that there exists at least three alternatively spliced forms of survivin, each containing distinct structural domains. 164, 165 It was suggested that these various forms of survivin differ in their ability to interact with other proteins involved in the regulation of apoptosis (or possibly with their ability to self-associate). Therefore, the role of survivin in apoptosis regulation may vary in a manner that is defined by the spectrum of survivin proteins present, and consequently, by the combinatorial protein-protein interactions that are permitted. In conclusion, it is tempting to envis-age therapeutic strategies based on molecules which activate the caspase cascade through inhibition of survivin for cancer cells that have acquired resistance to conventional chemotherapy ( Figure 2 ).
Concluding remarks
The mammalian caspases have been implicated in inflammation, proliferation and differentiation in recent years, although a detailed understanding of these emerging, nonapoptotic functions of the caspases awaits further analysis (Figure 1) . The caspases are also well-established components of the core apoptotic machinery, and the targeting of these proteases, as well as their inhibitors, constitutes an attractive approach in cancer treatment. However, successful drug treatment requires an adequate therapeutic index, ie the triggering of tumor-selective death without adverse side-effects on the host, 166 and apoptosis-based therapies will therefore need to intervene with considerable precision in order to avoid unrestricted killing of bystander cells. Moreover, monitoring of apoptosis alone may not suffice as an adequate predictor of therapeutic outcome, and should perhaps be complemented with the determination of clonogenic potential (see for example Ref. 167) . Notwithstanding these potential caveats, an increased molecular understanding of the pathways that govern apoptosis or resistance to apoptosis in normal and malignant cells is sure to add to our therapeutic armamentarium in the war against cancer.
